search
Back to results

Comparison of the Effect of Two Types of Physical Exercises in Patients With Heart Failure With Preserved Ejection Fraction (ExIC-FEp)

Primary Purpose

Heart Failure, Physical Exercise, Exercise Capacity

Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Combined exercise
High interval training
Sponsored by
University of Castilla-La Mancha
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Heart Failure

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Heart Failure with preserved ejection fraction picture (diagnosis according to ESC 2021 criteria) Signs and symptoms of Heart Failure A left ventricular ejection fraction of ≥50%. Objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of left ventricular diastolic dysfunction/elevated left ventricular filling pressures, including elevated natriuretic peptides. Sedentary men and women (structured exercise <2 x 30 min/week). Age ≥40 years Written informed consent Clinically stable for 6 weeks Optimal medical treatment for ≥6 weeks Exclusion Criteria: Non-cardiac causes of heart failure symptoms: Significant valvular or coronary artery disease - Uncontrolled hypertension or arrhythmias. Primary cardiomyopathies Significant pulmonary disease (FEV1<50% predicted, GOLD III-IV) Inability to exercise or conditions that may interfere with exercise intervention. Myocardial infarction in the last 3 months Signs of ischaemia during maximal cardiopulmonary exercise test. Comorbidity that may influence one-year prognosis 7. Participation in another clinical trial.

Sites / Locations

  • Universidad de Castulla-La ManchaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

No Intervention

Arm Label

Combined exercise

High interval training

Usual care

Arm Description

Outcomes

Primary Outcome Measures

Exercise capacity
Maximal cardiopulmonary stress test with Ergoline600 ergometer bicycle.
E velocity
E velocity in m/s
Endothelial function
Carotid intima-media thickness: by ultrasound with the Sonosite SII device.
Arterial stiffness
Pulse wave velocity and augmentation index
A velocity
A velocity in m/s
E/A ratio
E/A ratio
e' velocity
e' velocity in m/s
E/e' ratio
E/e' ratio
ejection fraction
percentage of ejection fraction
left ventricular volume index
left ventricular volume index
end-diastolic volume
end-diastolic volume
left ventricular mass
left ventricular mass
left atrial diameter
left atrial diameter
isovolume relaxation time
isovolume relaxation time in seg
deceleration time
deceleration time in m/s
left atrial volume index
left atrial volume index

Secondary Outcome Measures

Sociodemographic variables
Age, sex and socioeconomic level
Patient's medical history
Comorbidities and medication
Weight
Weight in kilogram
Muscular strength
Handgrip force to be determined with TKK 5401 Grip-D dynamometer.
Spirometry
Forced vital capacity (FVC), forced expiratory volume in the first second (FEV1) and FEV1/FVC ratio.
Glucose
Glucose
Physical activity
Accelerometry. Time of physical activity
HQoL
Validated 12-item health questionnaire (SF-12). From 0 to 12 (higher values better HQoL)
Adherence to the Mediterranean diet
Validated 14-item questionnaire on adherence to the Mediterranean diet (MEDAS-14). From 0 to 14 (higher values better Adherence)
height
height in centimeters
BMI
BMI in kg/m2
waist circumference
waist circumference in cm
body fat
percentage of body fat
blood pressure
systolic and diastolic blood pressure in mmHg
total cholesterol
total cholesterol
triglycerides
triglycerides
HDL-cholesterol
HDL-cholesterol
LDL-cholesterol
LDL-cholesterol
apolipoproteins A1 and B
apolipoproteins A1 and B
insulin
insulin
ultra-sensitive C-reactive protein
ultra-sensitive C-reactive protein
N-terminal pro-B-type natriuretic peptide (NT-proBNP)
N-terminal pro-B-type natriuretic peptide (NT-proBNP)
HbA1c
HbA1c

Full Information

First Posted
October 20, 2022
Last Updated
February 14, 2023
Sponsor
University of Castilla-La Mancha
search

1. Study Identification

Unique Protocol Identification Number
NCT05726474
Brief Title
Comparison of the Effect of Two Types of Physical Exercises in Patients With Heart Failure With Preserved Ejection Fraction
Acronym
ExIC-FEp
Official Title
Comparison of the Effect of Two Types of Physical Exercise on the Improvement of Exercise Capacity, Diastolic Function, Endothelial Function, and Arterial Stiffness in Patients With Heart Failure With Preserved Ejection Fraction (ExIC-FEp Study)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 23, 2023 (Actual)
Primary Completion Date
September 2024 (Anticipated)
Study Completion Date
September 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Castilla-La Mancha

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Background: Heart failure (HF) is a chronic disease with a very important and increasingly severe social and health impact with a prevalence of 6.8% in Spain. HF with preserved ejection fraction (HFpEF) represents approximately 50% of all patients with HF. In the absence of pharmacological treatments that have succeeded in reducing mortality or morbidity in this pathology, it is recommended that interventions be directed at prevention, symptomatic treatment of HF and treatment of comorbidities to avoid exacerbations, thus physical exercise is recognized as an important adjunct in the treatment of HF and is recommended by the guidelines of the American College of Cardiology (ACC)/American Heart Association (AHA) and the European Society of Cardiology (ESC). Currently, aerobic exercise is the most studied physical exercise in this population, but in recent years high-intensity interval training (HIIT) and the combination of aerobic exercise with strength training (combined exercise) have emerged. Objectives: The overall objective of this study is to compare the effectiveness of combined training and HIIT on exercise capacity, diastolic function, endothelial function, and arterial stiffness in patients with HFpEF. The specific objectives of this study are: a) to compare the effectiveness of combined training and HIIT on quality of life in patients with HFpEF and b) to analyze the cost-effectiveness of combined training and HIIT versus conventional treatment in patients with HFpEF. Methodology: The ExIC-FEp study will be a single-blind randomized clinical trial with 3 arms (combined exercise, HIIT and a control group), conducted at the Health and Social Research Center of the University of Castilla-La Mancha, to analyze two types of supervised physical exercise in patients with HFpEF for 6 months. Patients with HFpEF will be randomly assigned (1:1:1) to the combined exercise, HIIT or control group. All participants will be examined, at baseline (prior to randomization), at three months (mid-intervention) and at six months (at the end of the intervention). Participants will undergo physical examination, echocardiography, maximal cardiopulmonary stress test, and measurement of endothelial function and arterial stiffness. In addition, sociodemographic variables, quality of life, physical activity, adherence to the Mediterranean diet, strength, spirometry and blood sampling will be measured. Expected scientific contributions: this randomized clinical trial will represent a a significant advance in the scientific evidence available on the efficacy of physical exercise in the treatment of HFpEF, through: (a) transfer of the results to physicians, nurses and patients; (b) dissemination of results through scientific articles, doctoral theses and participation in congresses; (c) press releases and press conferences with the aim of disseminating the research results to the population; (d) dissemination through social networks to improve the social impact; and (e) design and content development of a web page.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure, Physical Exercise, Exercise Capacity, Diastolic Function, Endothelial Function, Arterial Stiffness

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
72 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Combined exercise
Arm Type
Experimental
Arm Title
High interval training
Arm Type
Experimental
Arm Title
Usual care
Arm Type
No Intervention
Intervention Type
Behavioral
Intervention Name(s)
Combined exercise
Intervention Description
Patients will exercise for 40 minutes three times a week on an ergometric bicycle at 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without ergometer at 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without shortness of breathing difficulty. In addition, strength training will be performed (bench press, leg press, leg curl, leg machine, bench press, leg press, leg curl, leg curl, leg machine). leg curls, leg curls, rowing machine, triceps dips, pectoral pull-ups) twice a week. week. Strength training will be performed with 15 repetitions per exercise and per session, with a corresponding workload of 15 repetitions. session, with a workload corresponding to 60% to 65% of the 1-repetition maximum (1RM) measured at (1RM) measured at the beginning and at the end of the intervention.
Intervention Type
Behavioral
Intervention Name(s)
High interval training
Intervention Description
Patients will perform three training sessions per week. Each training session begins with a 10-minute warm-up at moderate intensity (corresponding to 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, no shortness of breath) before cycling, four 4-minute intervals at high intensity (corresponding to 85-90% of VO2max, 90-95% of HRmax, 15-17 on the Borg scale, shortness of breath). Each interval will be separated by 3 minutes of active pauses, with a HRmax of 50-70%. The training session will end with 3 minutes of cool down at moderate intensity (corresponding to 50-60%). moderate intensity (corresponding to 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without difficulty). Borg scale, no shortness of breath). The total exercise time will be 40 minutes for the HIIT group.
Primary Outcome Measure Information:
Title
Exercise capacity
Description
Maximal cardiopulmonary stress test with Ergoline600 ergometer bicycle.
Time Frame
Change from Baseline exercise capacity at 3 months
Title
E velocity
Description
E velocity in m/s
Time Frame
Change from Baseline E velocity at 3 months
Title
Endothelial function
Description
Carotid intima-media thickness: by ultrasound with the Sonosite SII device.
Time Frame
Change from Baseline endothelial function at 3 months
Title
Arterial stiffness
Description
Pulse wave velocity and augmentation index
Time Frame
Change from Baseline arterial stiffness at 3 months
Title
A velocity
Description
A velocity in m/s
Time Frame
Change from Baseline A velocity at 3 months
Title
E/A ratio
Description
E/A ratio
Time Frame
Change from Baseline E/A ratio at 3 months
Title
e' velocity
Description
e' velocity in m/s
Time Frame
Change from Baseline e' velocity in m/s at 3 months
Title
E/e' ratio
Description
E/e' ratio
Time Frame
Change from Baseline E/e' ratio at 3 months
Title
ejection fraction
Description
percentage of ejection fraction
Time Frame
Change from Baseline ejection fraction at 3 months
Title
left ventricular volume index
Description
left ventricular volume index
Time Frame
Change from Baseline left ventricular volume index at 3 months
Title
end-diastolic volume
Description
end-diastolic volume
Time Frame
Change from Baseline end-diastolic volume at 3 months
Title
left ventricular mass
Description
left ventricular mass
Time Frame
Change from Baseline left ventricular mass at 3 months
Title
left atrial diameter
Description
left atrial diameter
Time Frame
Change from Baseline left atrial diameter at 3 months
Title
isovolume relaxation time
Description
isovolume relaxation time in seg
Time Frame
Change from Baseline isovolume relaxation time at 3 months
Title
deceleration time
Description
deceleration time in m/s
Time Frame
Change from Baseline deceleration time at 3 months
Title
left atrial volume index
Description
left atrial volume index
Time Frame
Change from Baseline left atrial volume index at 3 months
Secondary Outcome Measure Information:
Title
Sociodemographic variables
Description
Age, sex and socioeconomic level
Time Frame
Baseline
Title
Patient's medical history
Description
Comorbidities and medication
Time Frame
Baseline
Title
Weight
Description
Weight in kilogram
Time Frame
Change from Baseline weight at 3 months
Title
Muscular strength
Description
Handgrip force to be determined with TKK 5401 Grip-D dynamometer.
Time Frame
Change from Baseline Muscular strength at 3 months
Title
Spirometry
Description
Forced vital capacity (FVC), forced expiratory volume in the first second (FEV1) and FEV1/FVC ratio.
Time Frame
Change from Baseline spirometry at 3 months
Title
Glucose
Description
Glucose
Time Frame
Change from Baseline Glucose at 3 months
Title
Physical activity
Description
Accelerometry. Time of physical activity
Time Frame
Change from Baseline phisical activity at 3 months
Title
HQoL
Description
Validated 12-item health questionnaire (SF-12). From 0 to 12 (higher values better HQoL)
Time Frame
Change from Baseline HQoL at 3 months
Title
Adherence to the Mediterranean diet
Description
Validated 14-item questionnaire on adherence to the Mediterranean diet (MEDAS-14). From 0 to 14 (higher values better Adherence)
Time Frame
Change from Baseline Adherence to the Mediterranean diet at 3 months
Title
height
Description
height in centimeters
Time Frame
Change from Baseline height at 3 months
Title
BMI
Description
BMI in kg/m2
Time Frame
Change from Baseline BMI at 3 months
Title
waist circumference
Description
waist circumference in cm
Time Frame
Change from Baseline waist circumference at 3 months
Title
body fat
Description
percentage of body fat
Time Frame
Change from Baseline body fat at 3 months
Title
blood pressure
Description
systolic and diastolic blood pressure in mmHg
Time Frame
Change from Baseline blood pressure at 3 months
Title
total cholesterol
Description
total cholesterol
Time Frame
Change from Baseline total cholesterol at 6 months
Title
triglycerides
Description
triglycerides
Time Frame
Change from Baseline triglycerides at 6 months
Title
HDL-cholesterol
Description
HDL-cholesterol
Time Frame
Change from Baseline HDL-cholesterol at 6 months
Title
LDL-cholesterol
Description
LDL-cholesterol
Time Frame
Change from Baseline LDL-cholesterol at 6 months
Title
apolipoproteins A1 and B
Description
apolipoproteins A1 and B
Time Frame
Change from Baseline apolipoproteins A1 and B at 6 months
Title
insulin
Description
insulin
Time Frame
Change from Baseline insulin at 6 months
Title
ultra-sensitive C-reactive protein
Description
ultra-sensitive C-reactive protein
Time Frame
Change from Baseline ultra-sensitive C-reactive protein at 6 months
Title
N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Description
N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Time Frame
Change from Baseline N-terminal pro-B-type natriuretic peptide (NT-proBNP) at 6 months
Title
HbA1c
Description
HbA1c
Time Frame
Change from Baseline HbA1c at 6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Heart Failure with preserved ejection fraction picture (diagnosis according to ESC 2021 criteria) Signs and symptoms of Heart Failure A left ventricular ejection fraction of ≥50%. Objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of left ventricular diastolic dysfunction/elevated left ventricular filling pressures, including elevated natriuretic peptides. Sedentary men and women (structured exercise <2 x 30 min/week). Age ≥40 years Written informed consent Clinically stable for 6 weeks Optimal medical treatment for ≥6 weeks Exclusion Criteria: Non-cardiac causes of heart failure symptoms: Significant valvular or coronary artery disease - Uncontrolled hypertension or arrhythmias. Primary cardiomyopathies Significant pulmonary disease (FEV1<50% predicted, GOLD III-IV) Inability to exercise or conditions that may interfere with exercise intervention. Myocardial infarction in the last 3 months Signs of ischaemia during maximal cardiopulmonary exercise test. Comorbidity that may influence one-year prognosis 7. Participation in another clinical trial.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Iván Cavero-Redondo, PhD
Phone
+34675558830
Email
ivan.cavero@uclm.es
Facility Information:
Facility Name
Universidad de Castulla-La Mancha
City
Cuenca
ZIP/Postal Code
16001
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ivan Cavero-Redondo, PhD
Phone
'+34675568830
Email
ivan.cavero@uclm.es

12. IPD Sharing Statement

Learn more about this trial

Comparison of the Effect of Two Types of Physical Exercises in Patients With Heart Failure With Preserved Ejection Fraction

We'll reach out to this number within 24 hrs